English
日本語
한국어
简体中文
繁體中文
Italiano
español
Deutsch
Русский
With the help of a university professor and a psychiatrist, I created a project to discuss the function of pharmaceuticals in modifying synaptic plasticity linked with aging diseases, particularly Alzheimer's disease, and I presented it to the health comm
Kursinhalt
This presentation was developed in English.
The onset of neurodegenerative disorders has increased exponentially with age, suggesting that the brain is particularly susceptible to the aging process. Alzheimer's disease starts with an asymptomatic stage and biomarker evidence of the condition and progresses by expressing mild cognitive and/or neurobehavioral abnormalities until it reaches the state of dementia.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.
Rücktrittsregelung der/des TutorIn
Vor der Bestätigung einer Kursbuchung
- Stornierung jederzeit möglich
Nach der Bestätigung einer Kursbuchung
- Weniger als 24 Stunden vor Kursbeginn→ 50% des Kurspreises wird einbehalten.
- No-Show→ 100% des Kurspreises wird einbehalten.
Alle Kurse von dieser/m TutorIn
All Lessons
-
-
PORTUGUESE STEP BY STEP (SHORT VERSION)
Are you on a busy schedule? Even talking a little bit every day helps. This is a short 15 minute lesson!15 Min. 700P -
-
ENGLISH STEP BY STEP (SHORT VERSION)
Are you on a busy schedule? Even talking a little bit every day helps. This is a short 15 minute lesson!15 Min. 600P -
ENGLISH STEP BY STEP
This is a 30 minute break from your daily routine to practice your English speaking skills. Let's talk!30 Min. 1,200P -
Professional English Writing and Communication
"Professional English Writing and Communication" is a class designed to help non-native English speakers improve their ability to write effective and clear emails and paperwork in English.30 Min. 1,200P
